Drugs / AT19 cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04796688 | Mar 2021 → Mar 2023 | acute lymphoblastic leukemia, leukocyte disorder | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AT19 cells | “Cord blood derived T cells from healthy donor are the source for production of universal anti-CD19 CAR-modified AT19 cells.” NCT04796688 ↗ |
| Action | Deplete | “AT19 cells have exhibited potent cytotoxicity in CD19+ tumor cells” NCT04796688 ↗ |
| Modality | Cell therapy | “universal chimeric antigen receptor-modified AT19 cells” NCT04796688 ↗ |
| Target | CD19 | “universal anti-CD19 CAR-modified AT19 cells” NCT04796688 ↗ |